bluuebunny/crossref_metadata_2025_split huggingface dataset:
Oral anticandidal prophylaxis in patients undergoing chemotherapy for acute leukemia
Authors: Williams C. , Whitehouse J. M. A. , Lister T. A. , Wrigley P. F. M. 
Published: February 2007

AbstractFifty‐six untreated patients with acute leukemia (38 acute myelogenous leukemia, 16 acute lymphoblastic leukemia, and 2 blast crisis of chronic granulocytic leukemia) were randomized on admission to one of three groups – one to receive oral anticandidal prophylaxis through the period of remission induction chemotherapy with nystatin, another to receive natamycin, and the third to receive no anticandidal prophylaxis.Neither of the first two groups show any advantage over the last and it is concluded that provided gut sterilization regimes are not employed, prophylactic oral anticandidal treatment is of no value in these patients and should be reserved until there is clinical evidence of infection.
Chemotherapy of head and neck cancer: Combination treatment with cyclophosphamide, adriamycin, methotrexate, and bleomycin
Authors: Wittes Robert E. , Spiro Ronald H. , Shah Jatin , Gerold Frank P. , Koven Bernard , Strong Elliot W. 
Published: February 2007

AbstractA combination of cyclophosphamide, adriamycin, methotrexate, and bleomycin (CAMB) was explored in patients with advanced, nonresectable epidermoid carcinoma from primary sites in the head and neck, recurrent or persistent after radiation or surgery. Objective regression (greater than 50%) of measurable tumor was present in 35% of the patients. The median duration of response was 2.5 months. Median survival of responders was slightly less than the nonresponders, but the difference was not significant. Drug‐related morbidity was substantial; leukopenia, mucositis, and weight loss were the most frequent major side effects. Three deaths were attributable to the regimen. The results seem comparable to those one might expect from methotrexate alone.
The hemodialysis‐induced reaction in patients with leukemia
Authors: Berman M. A. 
Published: February 2007

AbstractThe white blood cell count response was documented in various patients following transfusions of 500 ml of autologous or unrelated donor blood that had been subjected to 10 minutes of dialysis with 15 minutes of stagnation. Patients studied included 1 patient with acute nonlymphocytic (ANLL) and 2 patients with chronic lymphocytic leukemia (CLL). The control group consisted of 4 patients with renal failure. The ANLL patient showed a normal two‐phase reaction after administration of donor's blood. It is possible that even under conditions of severe disturbance of hemopoiesis the general dependence on normal humoral regulation remains.The CLL patients showed a marked drop in circulating WBC in the first descending phase of the hemodialysis‐induced reaction (HDIR). All blood cell types including lymphocytes and blast cells took part in this decrease of blood count; this suggests a cell‐nonspecific effect. It is presumed that leukocytes that leave the circulation do not return into the blood and the procedure may be considered as a form of leukophoresis in vivo, with possible therapeutic value.
Ovarian cancer in children and adolescents: A review of 15 cases
Authors: Jereb B. , Golouh R. , Havliček S. 
Published: February 2007

AbstractFifteen patients, admitted between 1961 and 1975, from 8 to 19 years of age, with malignant ovarian tumors were reviewed. The histology was: dysgerminoma in 5, common “epithelial tumor” in 5, immature teratoma in 4, granulosa cell tumor in one. Of the 15 patients, 5 are alive and well, 4 of these had dysgerminoma, 1 had a papillary cystadenocarcinoma. Of 3 patients with dysgerminoma in Stage III, 2 are among the survivors. Dysgerminoma, in contrast with other types of germ cell tumors, may be curable even in advanced stage.
Connubial lymphoproliferative malignancies: A report of nine couples
Authors: Stephens Ronald L. , Larsen William E. , Holmes Fred F. , Clark Gary M. 
Published: February 2007

AbstractNine martial partners with lymphoproliferative malignancies are detailed and their cases summarized in Table I. This 30‐year observation represents the largest series of such associations from a single institution. A brief review of similar reported cases is presented.
Clinical evaluation of asaley
Authors: Bodey Gerald P. , Gottlieb Jeffrey A. , Burgess M. Andrew , Alexanian Raymond 
Published: February 2007

AbstractAsaley is an L‐leucine derivative of sarcolysin which is more active against some rodent tumors. Studies in the USSR demonstrated activity in patients with ovarian and breast carcinoma, Hodgkin's disease, and multiple myeloma. This study in 73 evaluable patients indicated that an appropriate oral dose for patients with adequate bone marrow is 800 mg/M2/day × 4 days at 5–6 week intervals. The most common toxicities were myelosuppression, nausea, and vomiting. Antitumor activity was observed in 2 of 24 evaluable patients with melanoma, and stabilization of previously progressive disease was observed in patients with adenocarcinoma of the colon, multiple myeloma, lymphoma, breast carcinoma, and thyroid carcinoma. Responses were minimal and of short duration but most of the patients had received extensive prior therapy.
Optimal use of L‐asparaginase (NSC‐109229) in acute lymphocytic leukemia
Authors: Jones Barbara , Holland James F. , Glidewell Oliver , Jacquillat Claude , Weil Marise , Pochedly Carl , Sinks Lucius , Chevalier Louise , Maurer Harold M. , Koch Kjell , Falkson Geoffrey , Patterson Richard , Seligman Barbara , Sartorius Jurg , Kung Faith , Haurani Farid , Stuart Marie , Burgert E. Omer , Ruymann Frederick , Sawitsky Arthur , Forman Edwin , Pluess Hansjuerg , Truman John , Hakami Nasrollah 
Published: February 2007

AbstractBetween 1971 and 1974, 646 evaluable patients under 20 years of age with previously untreated acute lymphocytic leukemia were treated according to Cancer and Leukemia Group B (formerly Acute Leukemia Group B) Protocol 7111. On a random basis, they received a 10‐day course of 1,000 units/kg/day of L‐asparaginase before, during, or after a 3‐week course of vincristine and corticosteroid. A control group received vincristine and corticosteroid for 4 weeks but no asparaginase. The overall complete remission rate was 85%, which was not altered significantly by any of the induction variables. Patients who received asparaginase for 10 days subsequent to vincristine and corticosteroid had a significantly longer complete remission duration with an estimated median of 45 months, compared to 20 months for the group receiving no asparaginase and 27 months for the other 2 asparaginase regimens. The beneficial effect of asparaginase was noted, irrespective of which 1 of the 2 intensification and maintenance programs the patients received. The 5‐year projection indicates a complete remission rate of 50% for those patients receiving subsequent asparaginase as compared to 41% of those induced on other regimens in this study and thus is superior to the use of only vincristine and corticosteroid.
Optic neuroretinitis in association with BCNU and procarbazine therapy
Authors: Mc. Lennan R. , Taylor H. R. 
Published: February 2007

AbstractA 53‐year‐old man with multiple myeloma and plasma cell leukemia developed severe, acute bilateral optic neuroretinitis 8 days after chemotherapy with BCNU, procarbazine, cyclophosphamide, and prednisolone. He showed some return of function over the following 6 weeks before his death. Both BCNU and procarbazine are known to cross the blood‐brain barrier. Procarbazine is known to interfere with neurological function. BCNU has been reported to transiently interfere with vision and, although this patient had highly morbid disease, the onset of optic neuroretinitis 8 days after combination therapy with these 2 drugs raises the possibility that one or both in combination may have been the cause of the optic neuropathy.
Repeated use of L‐asparaginase in multi‐drug therapy of childhood leukemia
Authors: Trueworthy Robert C. , Sutow Wataru W. , Pullen Jeanette , Komp Diane , Berry D. H. 
Published: February 2007

AbstractThe capacity of l‐asparaginase in two separate schedules (consecutive and intermittent), along with vincristine and prednisone to produce multiple responses, was evaluated in previously treated children with acute leukemia in relapse. The response rates varied inversely with previous l‐asparaginase exposure. A history of prior resistance to prednisone and vincristine appeared to reduce the response rate. Hypersensitivity reactions occurred in 14%.
Chemotherapeutic response in metastatic medulloblastoma: Report of two cases and a review of the literature
Authors: Nathanson Larry , Kovacs Szaboles Gabor 
Published: February 2007

AbstractMetastatic medulloblastoma is a rare clinical phenomenon. Review of the literature and the authors' experience reveals that when it occurs, palliation may be achieved with a variety of single and combination chemotherapy programs. Two objective responses with vincristine‐actinomycin‐D‐cyclophosphamide (VAC) and one each with adriamycin and methyl‐CCNU are described.
Positive monospot tests preceding the diagnosis of acute monocytic leukemia in two adolescents
Authors: Miale Thomas D. , Barbosa Jerry L. , Dellinger Charles T. , Wolfson Sorrell L. 
Published: February 2007

AbstractThe early detection and treatment of two cases of acute monocytic leukemia (AMoL) was hampered by the presence of positive slide tests for infectious mononucleosis (IM). This assumes great importance with the recent development of specific therapy, effective for certain subtypes of nonlymphocytic leukemia.
Nonbacterial thrombotic endocarditis in cancer patients: Comparison of characteristics of patients with and without concomitant disseminated intravascular coagulation
Authors: Bedikian Agop , Valdivieso Manuel , Luna Mario , Bodey Gerald P. 
Published: February 2007

AbstractThirty‐one cases with malignant neoplasm and nonbacterial thrombotic endocarditis (NBTE) were studied. A threefold increase in the incidence of NBTE over the five‐year period ending in 1976 was noticed. Seventy‐one percent of patients with NBTE had concomitant disseminated intravascular coagulation (DIC). Adenocarcinomas of the lung or ovary were the most common tumors (48%), followed by hematologic malignancies (25%). Five patients had acute leukemia, two of whom had received bone marrow transplantation. Sudden changes in the status of cardiovascular and central nervous sytems were the most common manifestations of NBTE and its complications. The possible predisposing factors included disseminated malignant neoplasms and infection with gram‐negative bacilli. Identification of high‐risk patients and early administration of preventive measures including anticoagulation might decrease the morbidity and mortality related to NBTE.
Thin needle biopsy of solid tumors in children
Authors: Jereb B. , Us‐Krasovec M. , Jereb M. 
Published: February 2007

AbstractThin needle biopsy of a suspected tumor will usually yield material amenable to cytologic examination and sufficient for diagnosis. Sixty children with suspected solid malignant tumors were subjected to this procedure. The masses biopsied were in bone, abdomen, mediastinum, tongue, pharynx, soft tissue, and peripheral lymph nodes.The diagnostic yield was 66% on first biopsy and rose to 93% on repeated biopsies. The diagnostic accuracy was 97% in malignant tumors with histologic confirmation. There were no proved false‐negative diagnoses, and two (3%) false‐positive (for malignancy) diagnoses. All patients were followed up. There were no complications of note.
Degradation and clearance of methotrexate in children with osteosarcoma receiving high‐dose infusion
Authors: Wang Yeu‐Ming , Kim Pyong‐Young , Lantin Erlinda , van Eys D. Catherine , Romsdahl Marvin M. , Sutow Wataru W. 
Published: February 2007

AbstractPlasma methotrexate (MTX) concentrations were quantitated in 34 patients after 127 high‐dose (35–350 mg/kg) infusions with citrovorum factor rescue. Significant linear correlations have been obtained between methotrexate dosage and concentrations in plasma at 6 and 24 hours after the initiation of the therapy. However, similar trends have not been observed when 48‐ and 72‐hour samples were analyzed. Clinical toxicity was not serious when the methotrexate level in plasma was < 4.5 × 10−6 M at 48 hours after the start of a six‐hour infusion in children. A minimal four‐hour steady‐state methotrexate plasma level can be maintained during a six‐hour infusion. Children excrete methotrexate at a faster rate than adults; the half‐life of MTX during the first phase of plasma clearance curve is one hour shorter in children. Urinary analyses have indicated that substantial methotrexate is metabolized. The chemical nature of these components has not been identified. Further, the urinary metabolic profiles varied among patients.
A phase II study of phenesterin (NSC‐104469)
Authors: Bennett J. M. , Frank J. , Sears M. , Lagakos S. W. , Horton J. , Colsky J. , Hall T. C. 
Published: February 2007

AbstractPhenesterin was evaluated in 222 patients with two different dosage regimens, one by daily treatment and the other with an intermittent schedule. Toxicity was moderate with both programs. The largest group of patients treated had breast cancer; they experienced a 10% response rate. Of interest was a higher percentage of responses in ovarian cancer (36%). An expanded study of patients with ovarian cancer would be of interest.
Combination chemotherapy with MOPP in children with recurrent brain tumors
Authors: Cangir Ayten , van Eys Jan , Berry D. H. , Hvizdala Eva , Morgan Samuel K. 
Published: February 2007

AbstractTwenty‐three children with CNS tumors were treated with combination chemotherapy including nitrogen mustard, vincristine sulfate, procarbazine, and prednisone (MOPP). All but one had progressive or recurrent tumors following surgery and irradiation. In addition, nine of these patients had prior chemotherapy. Seventeen out of 23 patients (73.4%) responded to MOPP chemotherapy including seven patients who had prior chemotherapy with single or multiple agents such as VCR, nitrosoureas, intrathecal methotrexate, and VM‐26. Three comatose patients who were being kept on Decadron® without benefit recovered from coma. At the time of this report 8 of the 17 responders are surviving without evidence of recurrence 7–30 months from the start of MOPP chemotherapy. In two of these children chemotherapy has been completely stopped.
Acute promyelocytic leukemia presenting as a pelvic mass
Authors: Belasco Jean Bello , Bryan J. Hugh , McMillan Campbell W. 
Published: February 2007

AbstractThe case history of a child with acute promyelocytic leukemia (APL) is reported to illustrate both an unusual presentation of APL as a pelvic mass and to review the pathophysiology and treatment of the disease. Therapy of APL consists of chemotherapy, namely adriamycin/daunomycin for remission induction, and of control of disseminated intravascular coagulation. A chloroma, if present, may require local irradiation in addition to chemotherapy. With aggressive management, the number of prolonged remissions may be greater for APL than for any other form of acute myelogenous leukemia (AML), with significant numbers of patients achieving five‐year survival.
Primary chemotherapeutic management of unresectable and metastatic hepatoblastoma in children: Report of four cases
Authors: Siegel Michael M. , Siegel Stuart E. , Isaacs Hart , Weitzman Jordan J. , Hanson Bruce A. , Higgins Gussie R. , Shore Nomie A. 
Published: February 2007

AbstractFour children presenting with unresectable hepatoblastomas and one with metastatic disease are reported. Following initial biopsy all were treated with chemotherapy which included Adriamycin. Three of the four children showed a significant reduction in tumor size, and in two, delayed resection of the primary lesion was possible. Chemotherapy including Adriamycin represents effective initial cytoreductive therapy for childhood hepatoblastoma, thereby reducing the morbidity and mortality associated with the extensive hepatic resection usually required for an untreated lesion.
Remission induction in acute myelogenous leukemia using cytosine arabinoside synchronization: A southwest oncology group study
Authors: Steuber C. Philip , Humphrey G. Bennett , McMillan Campbell W. , Vietti Teresa J. 
Published: February 2007

AbstractThe use of cytosine arabinoside (Ara‐C) infused at kinetically suggested intervals is reported in 40 pediatric patients with acute myelogenous leukemia (AML) and its subtypes. Response was observed in 17 of the 34 evaluable patients. However, the severe, often fatal effects of the regimen prevent its recommendation as a standard induction regimen in AML in children.
Combination chemotherapy of non‐Hodgkin lymphoma
Authors: Forcier R. Jackson , McLntyre O. Ross , Nissen Nis I. , Pajak Thomas F. , Glidewell Oliver , Holland James F. 
Published: February 2007

AbstractA randomized therapeutic trial of three induction regimens for patients with lymphosarcoma and reticulum‐cell sarcoma was conducted by the Cancer and Leukemia Group B (CALGB) (formerly Acute Leukemia Group B). Addition of streptonigrin, but not cyclophosphamide, to the combination of vincristine and prednisone improved the complete remission rate achieved after a 42‐day induction program. The duration of the subsequent remission and survival was not influenced by the induction combination assigned. Remission maintenance with cyclophosphamide was superior to maintenance with methotrexate. The results of this study are compared with others in which advantages for three or four drug treatment regimens have been reported.
Treatment of oat‐cell carcinoma of the lung in the community
Authors: Citronbaum Ronald 
Published: February 2007

AbstractNine patients with “limited” (thoracic) small‐cell lung carcinoma were treated with combined chemotherapy and radiotherapy (involved field and prophylactic whole brain). Induction drugs were Vincristine, Adriamycin, and Cyclophosphamide; and Cyclophosphamide, Vincristine, and CCNU for maintenance. Eight out of nine patients (89%) continue NED at a median follow‐up time of 12 months. This group is compared to 21 patients with more extensive disease and 6 patients with limited disease using various other regimens. Median survival in the extensive group was 5 months and 8 months for the limited‐diseased group treated with single agents. Intensive combination chemo‐irradiation therapy is safe and highly effective in patients with limited oat‐cell carcinoma of the lung, and leads to prolonged disease‐free survival.
Safe, rapid administration schedule for cis‐platinum—mannitol
Authors: Rainey John M. , Alberts David S. 
Published: February 2007

AbstractCis‐diamminedichloroplatinum (II) cis‐platinum, 25–75 mg/m2, with 40 gm mannitol and fluid were given over 1–2 hours to 40 patients with no evidence of elevated serum creatinine levels. Cis‐platinum was administered every 28 days at a dose of 50mg/m2 to 22 patients, and 75mg/m2 to 6 patients. Patients received from one to eight courses of therapy with no change in their serum creatinine level. A safe, simple method of cis‐platinum administration has been achieved.
Use of L‐asparaginase and cytosine arabinoside for refractory acute lymphocytic leukemia with particular reference to T‐cell leukemia
Authors: Steuber C. Philip , Levy Gary J. , Nix William L. , Shepherd Dell A. , Starling Kenneth A. , Fernbach Donald J. 
Published: February 2007

AbstractTen patients with late‐stage acute lymphocytic leukemia were treated with L‐asparaginase and cytosine arabinoside. Complete remission was achieved in 8 patients including 5 of 5 patients with T‐cell leukemia. Major toxicity included anaphylactic reactions in 3 of the 10 patients.
CCNU, vinblastine, and delalutin therapy in renal cell carcinoma
Authors: Vosika Gerald J. , Ryan Michael J. , Fortuny Ignacio A. , Meyer Cynthia , Kiang David T. , Theologides Athanasios , Kennedy Byrl J. 
Published: February 2007

AbstractAdvanced renal cell carcinoma is relatively resistant to most adequately evaluated chemotherapeutic agents. The combination of CCNU and vinblastine, which has antitumor activity in a frog renal carcinoma model system, has demonstrated activity in initial studies in man. The current study investigated this combination of drugs together with a progestational agent, Delalutin. Seventeen patients with metastatic renal cell carcinoma were treated with CCNU, vinblastine and Delalutin. There were no objective responses. Four patients with stable disease had a mean survival of 18 months compared to 13 patients with progressive disease who had a mean survival of 5 months. The survival of the four patients with stable disease was in large part due to the slowly progressive natural history of their disease.
Comparison of two radioimmunoassays and a microbiologic assay for bleomycin
Authors: Elson Michael K. , Oken Martin M. , Shafer Rex B. , Broughton Alan , Strong James , Braun C. T. , Crooke Stanley T. 
Published: February 2007

AbstractRecently two radioimmunoassays have been independently developed for determination of bleomycin levels. In this study these assays are compared with each other and with a standard microbiologic assay for bleomycin. Bleomycin levels were determined in serum and urine samples obtained at varying intervals following intramuscular bleomycin injection. There were systematic differences between the assays. One radioimmunoassay indicated bleomycin levels lower than the levels indicated by the microbiologic assay with serum samples. With urine samples, both radioimmunoassays indicated bleomycin levels greater than the microbiologic assay.
Bleomycin in combination chemotherapy of metastatic wilms tumor: A late recurrent case, refractory to conventional therapy
Authors: Kisielius Tomas , Bianco Adrian , Merrill John M. , Taylor S. G. , Dewys William 
Published: February 2007

AbstractA patient with a late recurrence (13 years) of Wilms tumor is presented. After relapse with conventional chemotherapy, an objective partial remission was obtained with bleomycin, vinblastine, cyclophosphamide, and cis‐platinum. Stable disease was noted when bleomycin was withheld. Bleomycin in this combination appeared to effect a good response, and further studies of chemotherapy of Wilms tumor should include bleomycin in combination with other active agents.
Serial studies of serum dopamine‐B‐hydroxylase and urinary vanillylmandelic and homovanillic acids in neuroblastoma
Authors: Brewster M. A. , Berry D. H. 
Published: February 2007

AbstractRecent reports have suggested that elevations of serum dopamine‐B‐hydroxylase (DBH) activity may correlate with diagnosis in neuroblastoma patients excreting vanillylmandelic acid (VMA). We have serially studied serum DBH and urinary homovanillic acid (HVA) and VMA excretion during the disease course of five patients with neuroblastoma. DBH activities did not indicate clinical course, therapies, or prognosis. Dilution studies revealed an age‐related alteration in DBH effectors and they suggest that these may be different in neuroblastoma.